U.S., Jan. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07311564) titled 'A Study of LAD603 in Adults With Alopecia Areata' on Dec. 29, 2025.
Brief Summary: The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.
Study Start Date: Dec. 17, 2025
Study Type: INTERVENTIONAL
Condition:
Alopecia Areata
Intervention:
DRUG: LAD603
LAD603 administered subcutaneously.
OTHER: Placebo
LAD603 matching placebo administered subcutaneously.
Recruitment Status: RECRUITING
Sponsor: Almirall, S.A.
Disclaimer: Cur...